Immunotherapy of Breast Cancer Using Novel Her2/Neu-Based Vaccines
Annual summary rept. 25 Mar 2002-24 Mar 2003
PENNSYLVANIA UNIV PHILADELPHIA
Pagination or Media Count:
Current breast cancer therapy consisting of surgery, radiation and chemotherapy, fails in 44,000 women per year. Radiation and chemotherapy can also cause significant side effects. New and improved therapies need to be developed to cure patients who fail other therapies. Recently, Her2neu has been described as a breast cancer antigen because it is overexpressed on 25-40 of all breast cancers. Her2neu is only expressed at very low levels on normal cells therefore, it is an appropriate target for the design of immunotherapeutics specific for breast cancer. Our lab has used Listeria monocytogenes as a vaccine vector for cancer because it induces strong CD4 and CD8 T cell responses.
- Medicine and Medical Research